Table I.
Demographic, clinical and angiographic parameters of SCF and control group
| Variable | SCF group (n=40) | Control group (n=40) | Value of p |
|---|---|---|---|
| Gender (male/female) | 20/20 | 19/21 | 0.82 |
| Age [years] | 55.0 ±9.5 | 53.9 ±8.2 | 0.32 |
| Height [cm] | 167 ±7 | 165 ±16 | 0.15 |
| Weight [kg] | 78.5 ±9.5 | 76.4 ±11.6 | 0.38 |
| BMI [kg/m2] | 28.0 ±3.1 | 28.1 ±3.6 | 0.82 |
| Pulse [beats/min] | 74 ±8 | 74 ±10 | 0.92 |
| Systolic BP [mm Hg] | 128.0 ±23.5 | 130.1 ±29.2 | 0.10 |
| Diastolic BP [mm Hg] | 75.9 ±13.9 | 74.4 ±14.9 | 0.38 |
| Hypertension, n (%) | 18 (45) | 18 (45) | 1.00 |
| Diabetes mellitus, n (%) | 8 (20) | 9 (22.5) | 0.79 |
| Hyperlipidemia, n (%) | 12 (30) | 11(27.5) | 0.81 |
| Smoking, n (%) | 9 (22.5) | 8 (20) | 0.79 |
| Alcohol, n (%) | 9 (22.5) | 4 (10) | 0.13 |
| CAD family history, n (%) | 14 (35) | 13 (32.5) | 0.81 |
| Total cholesterol [mg/dl] | 194.5 ±39.7 | 199.1 ±47.4 | 0.23 |
| LDL-cholesterol [mg/dl] | 129.2 ±39.7 | 127.1 ±37.2 | 0.79 |
| HDL-cholesterol [mg/dl] | 39.6 ±10.1 | 39 ±11.8 | 0.91 |
| Triglyceride [mg/dl] | 156.4 ±74.5 | 160.4 ±97.6 | 0.72 |
| Urea [mg/dl] | 34 ±8 | 35 ±11 | 0.68 |
| Creatinine [mg/dl] | 0.9 ±0.3 | 0.9 ±0.3 | 0.96 |
| Aspirin use, n (%) | 22 | 15 | 0.11 |
| β-Blocker, n (%) | 8 | 11 | 0.43 |
| Calcium channel-blocker, n (%) | 10 | 7 | 0.41 |
| TFC (frame/s): | |||
| LAD | 61.7 ±20.5 | 29.0 ±5.8 | < 0.001 |
| CX | 36.2 ±10.6 | 21.3 ±3.5 | < 0.001 |
| RCA | 39.7 ±12.6 | 20.0 ±3.8 | < 0.001 |
| Mean TFC (frame/s) | 45.8 ±8.8 | 24.4 ±2.9 | < 0.001 |
| SPA [U/l] | 702.7 ±13.8 | 683.9 ±13.2 | < 0.001 |
Data presented as mean±SD, SCF – slow coronary flow, NS – non-significant, BMI – body mass index, CAD – coronary artery disease, LDL – low-density lipoprotein, HDL – high-density lipoprotein, TFC – TIMI frame count, LAD – left anterior descending artery, CX – circumflex artery, RCA – right coronary artery, SPA – serum prolidase activity.